Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapeutics entities : Sarepta therapeutics, inc. save search
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
Published: 2024-04-24 (Crawled : 13:00) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
first therapeutics financial results
Sarepta Therapeutics to Present at Upcoming Investor Conferences - March 4, 2024
Published: 2024-03-04 (Crawled : 14:00) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -3.72%
therapeutics
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
Published: 2024-02-28 (Crawled : 00:00) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: -0.28%
H: 1.03%
C: -2.58%
therapeutics financial results
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
Published: 2024-02-21 (Crawled : 15:30) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: -0.97%
H: 1.06%
C: -1.88%
therapeutics financial results
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
Published: 2024-02-16 (Crawled : 15:00) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: 12.15%
H: 2.1%
C: -3.89%
fda therapeutics
Global Cell Penetrating Peptide Market Forecast Report to 2030, Featuring Biosynth, Creative Peptides, Cupid Peptide, Alta Bioscience, AnaSpec, Peptomyc, PolyPeptide, Bachem & Sarepta Therapeutics
Published: 2024-02-05 (Crawled : 11:00) - prnewswire.com
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: 0.12%
H: 3.45%
C: 3.4%
RVNC | $3.57 -2.46% -2.52% 1.8M
|
Health Technology
|
| O: -2.42%
H: 1.05%
C: -2.67%
report cell global therapeutics market
Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
Published: 2024-01-29 (Crawled : 15:30) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: 0.06%
H: 3.66%
C: 1.43%
srp-5051 positive therapeutics duchenne study
Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Published: 2024-01-16 (Crawled : 23:00) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: -1.19%
H: 1.04%
C: -0.02%
srp-9003 treatment therapeutics study
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
Published: 2024-01-08 (Crawled : 00:00) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: -0.2%
H: 5.95%
C: 5.62%
revenue therapeutics
Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-02 (Crawled : 20:00) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: -0.96%
H: 1.88%
C: 0.74%
conference therapeutics
Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status
Published: 2023-12-22 (Crawled : 20:00) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: 1.37%
H: 3.21%
C: 2.77%
label therapeutics duchenne
Sarepta Therapeutics to Present at the UBS Biopharma Conference
Published: 2023-11-02 (Crawled : 15:00) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: 3.8%
H: 3.51%
C: -2.1%
conference biopharma therapeutics
Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy
Published: 2023-10-30 (Crawled : 22:00) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: 1.05%
H: 1.86%
C: -0.28%
global topline therapeutics duchenne therapy results study
Pompe Disease Market to Exhibit Significant Growth by 2032, Predicts DelveInsight | Leading Companies - Asklepios Biopharmaceutical, Inc., Astellas Pharma Inc., Amicus Therapeutics, Sanofi, Spark Therapeutics
Published: 2023-10-26 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -18.18%
H: 0.0%
C: 0.0%
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: 4.02%
H: 0.0%
C: -4.32%
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: 0.27%
H: 0.0%
C: -4.53%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -15.73%
H: 0.0%
C: 0.0%
pharma disease companies therapeutics growth market
Sarepta Therapeutics to Announce Third Quarter 2023 Financial Results
Published: 2023-10-25 (Crawled : 13:00) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: -0.91%
H: 0.24%
C: -4.58%
therapeutics financial results
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
Published: 2023-10-16 (Crawled : 12:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 2.24%
H: 3.32%
C: 1.34%
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: -0.18%
H: 1.11%
C: -0.17%
CRSP | News M | $55.66 -1.33% -1.35% 910K
|
Health Technology
|
| O: 0.0%
H: 1.67%
C: 1.13%
crispr therapeutics
RNA Therapeutics Market worth $18.0 billion | MarketsandMarkets
Published: 2023-09-15 (Crawled : 15:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 1.53%
H: 0.0%
C: 0.0%
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: 0.0%
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: 3.0%
H: 0.0%
C: -3.43%
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.26%
H: 1.04%
C: 0.03%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 1.51%
H: 0.26%
C: -0.72%
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: -0.27%
H: 0.54%
C: -0.84%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: 0.16%
H: 2.0%
C: 1.42%
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: -0.57%
H: 0.35%
C: -1.11%
BNTX | News | $88.18 -0.35% -0.35% 280K
|
Health Technology
|
| O: 0.17%
H: 0.48%
C: -0.82%
ARWR | $23.285 -2.08% -2.13% 810K
|
Health Technology
|
| O: 0.16%
H: 0.46%
C: -5.46%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.74%
H: 2.42%
C: -3.47%
therapeutics market
Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year
Published: 2023-09-07 (Crawled : 14:30) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: -0.2%
H: 0.2%
C: -0.51%
year therapeutics duchenne
Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Published: 2023-09-05 (Crawled : 14:30) - biospace.com/
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: 0.01%
H: 0.0%
C: 0.0%
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: -0.38%
H: 0.42%
C: -1.2%
conference global therapeutics
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 01, 2023
Published: 2023-08-01 (Crawled : 07:00) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: -0.36%
H: 0.03%
C: -0.44%
nasdaq grants therapeutics
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.